On December 16, 2025, Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) announced that it has entered into an exclusive license, collaboration and distribution agreement with Glenmark Specialty S.A. (Glenmark) for Aumolertinib, a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC).
Under the License Agreement, Hansoh Pharma grants an exclusive license to Glenmark to develop and commercialize Aumolertinib across its licensed territories: the Middle East and Africa, Southeast & South Asia, Australia, New Zealand, Russia/CIS and a few selected Caribbean countries covered by the agreement. Hansoh Pharma will receive an upfront payment followed by potential regulatory and commercial milestone payments possibly cumulating to over US$1 billion, in addition to tiered royalties on net sales in the licensed territories.
About Aumolertinib
Ameile (Aumolertinib Mesilate Tablets) is the first original third-generation EGFR-TKI innovative drug in China. It has been approved for four indications in China, namely: in March 2020, it was approved for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy; in December 2021, it was approved as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive; in March 2025, it was approved for the treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following definitive platinum-based chemoradiotherapy whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutations; in May 2025, it was approved for the adjuvant treatment of adult patients with stage II to IIIB NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, and who have undergone tumor resection with or without prior adjuvant chemotherapy as determined by their physician. Additionally, in June 2025, Aumolertinib (trade name in the United Kingdom: Aumseqa®) was approved by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom (MHRA) for marketing.
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2022; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2022. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3 million lives over the last decade through its CSR interventions.
